



IPW
AF

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

10

Application Number

09/919,195

Filing Date

July 31, 2001

First Named Inventor

Massaro

Art Unit

1625

Examiner Name

D. Margaret Seaman

Attorney Docket Number

17293DIV(HL)

ENCLOSURES (Check all that apply)

☐

Fee Transmittal Form

☐

Fee Attached

☐

Amendment/Reply

☐

After Final

☐

Affidavits/declaration(s)

☐

Extension of Time Request

☐

Express Abandonment Request

☐

Information Disclosure Statement

☐

Certified Copy of Priority Document(s)

☐

Response to Missing Parts/
Incomplete Application

☐

Response to Missing Parts
under 37 CFR 1.52 or 1.53

☐

Drawing(s)

☐

Licensing-related Papers

☐

Petition

☐

Petition to Convert to a
Provisional Application

☐

Power of Attorney, Revocation
Change of Correspondence Address

☐

Terminal Disclaimer

☐

Request for Refund

☐

CD, Number of CD(s) _____

☐

After Allowance communication
to Technology Center (TC)

☐

Appeal Communication to Board
of Appeals and Interferences

☒

Appeal Communication to TC
(Appeal Notice, Brief, Reply Brief)

☐

Proprietary Information

☐

Status Letter

☐

Other Enclosure(s) (please
Identify below):

Remarks

Please apply any deficiencies or overpayments to deposit account 502362.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm
or
Individual name

Gabor L. Szekeres

Signature

Gabor L. Szekeres

Date

May 27, 2005

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name

Toni Whyte

Signature

Toni Whyte

Date

5-27-05

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

17293 DIV



PATENT


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
) Examiner: D. Margaret
) Seaman
Massaro et al.)
) Art Unit: 1625
Serial No.: 09/919,195)
)
Filed: July 31, 2001)
)
For: METHODS AND COMPOSITIONS FOR)
THE TREATMENT AND PREVENTION)
OF LUNG DISEASE)

Certificate of Mailing

I hereby certify that this correspondence is being deposited on May 27, 2005 with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O.Box 1450, Alexandria VA 22313-1450 Mail Stop

Appeal Brief



Toni Whyte

Date: May 27, 2005

17293 DIV

Reply to Examiner's Answer

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE =
BEFORE THE BOARD OF APPEALS

APPELLANT'S REPLY TO EXAMINER'S ANSWER PURSUANT TO
CONSOLIDATED PATENT RULES § 41.41

Honorable Commissioner of Patents
P.O.Box 1450
Alexandria, VA 22313-1450

In accordance with Consolidated Patent Rules 41.41 Appellant hereby
submits its Reply to the Examiner's Answer.

REASONED STATEMENT AGAINST EXAMINER'S ANSWER THAT
MAINTAINS THE REJECTION PURSUANT TO 35 U.S.C. Sections 112,
first paragraph, AND Section 102(b)

Argument against rejection for alleged anticipation

Applicant respectfully disagrees with the Examiner's statement regarding the grouping of claims (Page 3, paragraph 7 of the Examiner's answer) wherein the Examiner asserts that all claims (Claim 13 – 28) stand or fall together because Appellant's brief does not include a statement and support for the statement that certain claims, or groups of claims, require independent evaluation for patentability under 35 U.S. C. Section 102(b). This assertion by the Examiner is in error. On page 8 of the Appeal Brief applicant argues that:

“with respect to the rejection pursuant to 35 U.S.C. § 102 the claims should be divided in at six separate groups of inventiveness and the erroneous nature of this rejection merits discussion with respect to each group.”

Indeed, on page 14 *et sequitur* the Appeal Brief provides a cogent statement regarding each of the six claim groups. Each of these groups should be adjudged separately for the purposes of novelty in view of the references of record. The different novel aspects of the claims termed “additional inventive features” are described on pages 3 to 6 of the Appeal Brief.

The Examiner's position regarding the claims having the differing and/or additional inventive features is, in substance, that such features are inherent in the prior art. This is in error because the claimed features are the very particular action of the compounds on several types of retinoid

receptors. Claim 13 states that the compound to be used in the claimed method is an *antagonist* of retinoid receptors of the RAR β type, does not modulate RXR receptors and not specific to at least one other RAR receptor subtype (namely, not specific to at least one of the RAR α and RAR γ subtypes). Additional claims define the compound used in the claimed method as being not specific to RAR α (claim 14), or as not specific to RAR γ (Claim 15) etc. (See the “Summary of Claimed Subject Matter” in the Appeal Brief.)

Because the cited references do not disclose the above-noted and other (recited in the claims) specific behavior towards the different types of retinoid receptors, there is a *logical inconsistency* in the Examiner’s position that these characteristics are inherent in the compounds of prior art used for treating certain lung conditions. Applicant respectfully submits that if a prior art compound was to inherently have the characteristic of, for example of the compound required in Claim 14, and also the characteristics of the compound required in Claim 15, then Claims 14 and 15 would be redundant in view of Claim 13. Clearly, the recited characteristics are different as far as the RAR α and RAR γ subtypes are concerned. For this reason alone the rejection pursuant to section 102(b) is in error when its main support is that the claimed characteristics are nowhere mentioned but are nevertheless inherent in the prior art compounds.

It also follows from the foregoing that whereas the cited prior art compounds may have beneficial effects on lung disorders, the presently claimed method does not merely reflect a discovery of the mode of action of an already known drug. Whereas Applicant agrees with the Examiner’s position exemplified by the Examiner’s reference to “aspirin” (see page 10,

second paragraph of the Examiner's answer) the present invention clearly involves more than just the discovery of the mode of action of previously known compounds which allegedly "inherently" have the characteristics required in the instant claims.

Without actually testing and knowing the behavior of the compounds used in prior art methods towards the receptors recited in the instant claims the Examiner has no basis to assert that these characteristics are inherent in the prior art methods of treating lung diseases or treating alveolar destruction.

For these reasons and the other reasons set forth in Appellant's Brief on Appeal, making all claims stand or fall together regarding the issue of novelty is in serious error. Because the inherency argument used for the rejection leads to a logical inconsistency and has no basis in actual fact, the requirement that any "anticipating" reference must disclose in its four corners all features of the claims has not been met in the rejection and should be strictly enforced in this appeal. The rejection pursuant to 35 U.S.C section 102(b) should be reversed as its main support of inherency has been shown to be in error.

Argument against rejection pursuant to 35 U.S.C. Section 112, first paragraph for failure to comply with the written description requirement

The Examiner's Answer states (see page 5) that applicant's argument is that the statute does not require clarity but merely to put Applicant's invention into the possession of the public. Applicant respectfully submits that this statement does not describe accurately Applicant's position on this issue. Applicant's position on this issue is that the written description of the instant patent application clearly describes Applicant's invention, and clearly

places the claimed method in the possession of those having ordinary skill in the art pertaining to methods of treatment by retinoid and like compounds.

In the Answer to Applicant's Brief on Appeal the Examiner acknowledges that the "assay needed to determine if a candidate compound has the instantly claimed activity is routine and within the skill of the ordinary artisan". (page 11 of the Examiner's Answer). Thus, the Examiner does not dispute that this routine assay is adequately described or referenced in the instant application. Nevertheless, the Examiner is of the position that because the application does not describe a "core compound" or a class of "core compounds" the skilled artisan would not know what compounds to test, and for this reason the description fails to fulfill the statutory requirement of Section 112.

Applicant respectfully submits that the Examiner's position on this issue is in error. First, it is noted that the ordinary artisan in this field is well familiar with the concept and nature of "retinoids", "retinoid-like" and retinoid-antagonist-like" compounds and is highly likely to recognize such potential biological characteristics from the chemical structural formulas of a large class of compounds. Moreover, in view of a very substantial number of US and foreign patents as well as of scientific publications that disclose "retinoids", "retinoid-like" and retinoid-antagonist-like" compounds an ordinary artisan can readily perform a literature search which would readily lead the artisan to the class of compounds to be assayed in accordance with the teachings of the present disclosure.

Still further, the passage on Page 12 line 30 through page 13 line 8 of the instant specification incorporates by reference U.S. Patent Nos. 5,739,338; 5,728,846; 5,760,276 and 5,877,207, each of which describes "the synthesis of RAR ligands having antagonist and/or inverse agonist

activity. These patents have general formulas of broad scope and also list numerous exemplary compounds of specific disclosed structure. The “ordinary artisan” is highly likely to consider the compounds of these references and other structurally similar compounds as potential candidates for screening in the assays clearly established in the art and referenced in the instant specification. For this reason the Examiner’s assertion is in error that the instant application does not provide a “core compound” or likely candidate for the assay in search for the biological properties required by the instant claims.

Thus, the Examiner’s position (page 13 of the Answer) that it is not within the skill of the ordinary artisan to choose the compounds that should be put on the screening assays is in error. The ordinary artisan having the general high knowledge regarding “retinoids”, “retinoid-like” and retinoid-antagonist-like” compounds, coupled with the ready availability of pertinent literature and in view of the referenced examples provided in the specification is not required to do an “undue amount” of experimentation while assaying compounds for the required biological activities.

It appears that in accordance with the Examiner’s view, pursuant to 35 U.S.C. Section 112 a class of compounds to be used in a claimed method cannot be defined for the purposes of an enabling disclosure by biological characteristics and must be defined strictly by chemical formula. However, this requirement or result is not supported by the clear language of the statute, where it is stated:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set

forth the best mode contemplated by the inventor of carrying out his invention. (35 U.S.C. Section 112, first paragraph)

Applicant/Appellant respectfully submits that the just quoted requirements of the statute have been fully satisfied in the instant specification with regard to identifying compounds to be used in the claimed method. The foregoing is also intended as a specific refutation of the Examiner's discussion of the *In re Wands* factors, which according to the Examiner, would support the rejection pursuant to 35 U.S.C. section 112, first paragraph.

In her Answer the Examiner also asserts that the specification fails to teach the application of the claimed method, that is the mode of administration of the compounds used in the method and the precise nature of the diseases to be treated by the claimed method. Applicant respectfully submits that this assertion of the Examiner is also in error.

Alveolar destruction in a mammal (Claim 13) is a condition which is well known and needs no further description in a contemporary application for patent. Ordinary artisans in the healing arts know the nature and specific names of diseases which involve or result in "alveolar destruction". Moreover, the introductory section of the instant application for patent describes the nature of "alveolar destruction" and provides examples such as bronchopulmonary dysplasia (BPD) and emphysema as examples. Diseases and conditions of a mammal which benefit from increasing "the gas-exchange surface area of a mammalian lung" (Claim 21) are also well known by ordinary artisans in the healing arts, and the diseases of bronchopulmonary dysplasia (BPD) and emphysema serve as examples. (See page 2 lines 5 to 14 and page 11 lines 21 to 25 of the instant specification). Thus, the specification clearly teaches to the ordinary artisans the nature of the diseases and conditions treatable by the claimed methods.


As far as modes of administration and dosages are concerned, it is well known in the art that dosage of a drug to be administered depends on multiple factors, such as the precise nature (chemical identity) of the drug, the nature of severity of the disease or condition to be treated and the nature age and condition of the subject to be treated (human or other mammal) and on the precise mode of administration. It is also well known in the art that drugs can be administered in multiple ways which include systemic administration (for example, oral, intravenous or intraperitoneal) topical, and in case of drugs involving lung tissue as an inhalant. The instant specification discloses that these modes of administration are applicable in the claimed method (see page 12 lines 6 to line 30 of the instant specification) and for preferred embodiment describes administration in the form of “an inhalant as a powdered or liquid aerosol” (page 12 lines 1- 15).

The art is well aware that the precise dosage and mode of administration is determined in each particular case of patient and condition by *routine* experimentation and experience. Such routine experimentation is not considered in violation of the enabling and best mode requirements of 35 U.S.C. Section 112.

CONCLUSION

In light of the foregoing the rejection of Claim 13 – 28 pursuant to 35 U.S.C Sections 102(b) and 112, first paragraph is in error. The Examiner Answer has not refuted successfully the reasons for this appeal set forth in Appellant's Brief on Appeal, and the rejections should be reversed.

Respectfully submitted



Date:

Gabor L. Szekeres

Registration number 28,675